Spots Global Cancer Trial Database for zimberelimab
Every month we try and update this database with for zimberelimab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | NCT06120075 | Advanced Cancer | AB801 Zimberelimab Docetaxel | 18 Years - | Arcus Biosciences, Inc. | |
| A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma | NCT05900765 | Classical Hodgk... | Zimberelimab 24... | 18 Years - | Sun Yat-sen University | |
| Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC | NCT06055738 | Locally Advance... | Zimberelimab Albumin-bound P... Cisplatin | 18 Years - | Tang-Du Hospital | |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | NCT04772989 | Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc... | AB308 Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer | NCT04736173 | Non Small Cell ... Nonsquamous Non... Squamous Non Sm... Lung Cancer | Domvanalimab Zimberelimab Carboplatin Paclitaxel Pemetrexed Pembrolizumab | 18 Years - | Arcus Biosciences, Inc. | |
| A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | NCT03846310 | Non Small Cell ... Non Small Cell ... Nonsquamous Non... Sensitizing EGF... | Etrumadenant Zimberelimab Carboplatin Pemetrexed Pembrolizumab | 18 Years - | Arcus Biosciences, Inc. | |
| Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | NCT05688215 | Borderline Rese... Locally Advance... | Biospecimen Col... Computed Tomogr... Core Biopsy Fluorouracil Irinotecan Leucovorin Leucovorin Calc... Oxaliplatin Quemliclustat Zimberelimab | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma | NCT05130177 | Melanoma | Zimberelimab Domvanalimab | 18 Years - | University of Pittsburgh | |
| Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC | NCT06055738 | Locally Advance... | Zimberelimab Albumin-bound P... Cisplatin | 18 Years - | Tang-Du Hospital | |
| SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) | NCT06009029 | Locally Advance... | Stereotactic bo... Zimberelimab (G... | 18 Years - 75 Years | Peking University Third Hospital | |
| Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer | NCT05824468 | Cervical Cancer Cervical Carcin... | Zimberelimab Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | NCT05886634 | Dedifferentiate... Soft Tissue Sar... Sarcoma,Soft Ti... Sarcoma Recurrent Dedif... Unresectable De... Metastatic Dedi... | Etrumadenant Zimberelimab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma | NCT06048484 | Pancreatic Duct... | Stereotactic bo... Zimberelimab Quemliclustat Etrumadenant Modified FOLFIR... | 18 Years - | Columbia University | |
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | NCT05886634 | Dedifferentiate... Soft Tissue Sar... Sarcoma,Soft Ti... Sarcoma Recurrent Dedif... Unresectable De... Metastatic Dedi... | Etrumadenant Zimberelimab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer | NCT04262856 | Non Small Cell ... Nonsquamous Non... Squamous Non Sm... Lung Cancer | Domvanalimab Etrumadenant Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) | NCT06009029 | Locally Advance... | Stereotactic bo... Zimberelimab (G... | 18 Years - 75 Years | Peking University Third Hospital | |
| Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | NCT04791839 | Non Small Cell ... Non-small Cell ... Non-small Cell ... | Zimberelimab Domvanalimab Etrumadenant | 18 Years - | Washington University School of Medicine | |
| Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer. | NCT06128460 | Cervical Cancer | Zimberelimab Platinum radiotherapy | 18 Years - 70 Years | Obstetrics & Gynecology Hospital of Fudan University | |
| Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | NCT04791839 | Non Small Cell ... Non-small Cell ... Non-small Cell ... | Zimberelimab Domvanalimab Etrumadenant | 18 Years - | Washington University School of Medicine | |
| A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | NCT03628677 | Solid Tumor, Un... | Domvanalimab Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | NCT05568095 | Advanced Upper ... | Domvanalimab Zimberelimab Capecitabine Fluorouracil Leucovorin Oxaliplatin Nivolumab | 18 Years - | Arcus Biosciences, Inc. | |
| Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) | NCT06048133 | Biliary Tract C... Cholangiocarcin... Bile Duct Cance... | Gemcitabine Cisplatin Zimberelimab Quemliclustat | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors | NCT04087018 | Advanced Solid ... | zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer | NCT05824468 | Cervical Cancer Cervical Carcin... | Zimberelimab Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma | NCT04854499 | Head and Neck S... | Magrolimab Pembrolizumab Docetaxel 5-FU Cisplatin Carboplatin Zimberelimab | 18 Years - | Gilead Sciences | |
| Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer | NCT06166589 | Previously AG C... | Zimberelimab Oxaliplatin S-1 Irinotecan | 18 Years - | Shanghai Zhongshan Hospital | |
| Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers | NCT05891171 | Advanced Cancer Advanced Malign... Bladder Cancer Cervical Cancer Esophageal Canc... Gastric Cancer Gastroesophagea... Head and Neck S... Non-Small Cell ... Ovarian Cancer Renal Cell Carc... Triple Negative... | AB598 Zimberelimab Carboplatin Pemetrexed Fluorouracil Leucovorin Oxaliplatin | 18 Years - | Arcus Biosciences, Inc. | |
| PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer | NCT06133517 | Urothelial Blad... | Sacituzumab gov... Zimberelimab Domvanalimab | 18 Years - | Fundación para el Progreso de la Oncología en Cantabria | |
| Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer | NCT05824468 | Cervical Cancer Cervical Carcin... | Zimberelimab Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer | NCT05915442 | Oligometastatic... | Quemliclustat Etrumadenant Zimberelimab Stereotactic Bo... | 18 Years - 99 Years | Columbia University | |
| A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body | NCT05568095 | Advanced Upper ... | Domvanalimab Zimberelimab Capecitabine Fluorouracil Leucovorin Oxaliplatin Nivolumab | 18 Years - | Arcus Biosciences, Inc. | |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05177770 | Metastatic Cast... Prostate Cancer | SRF617 etrumadenant zimberelimab | 18 Years - | Coherus Biosciences, Inc. | |
| Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer | NCT06166589 | Previously AG C... | Zimberelimab Oxaliplatin S-1 Irinotecan | 18 Years - | Shanghai Zhongshan Hospital | |
| A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | NCT06120075 | Advanced Cancer | AB801 Zimberelimab Docetaxel | 18 Years - | Arcus Biosciences, Inc. | |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | NCT03547973 | Metastatic Urot... | Sacituzumab Gov... Pembrolizumab Cisplatin Avelumab Zimberelimab Carboplatin Gemcitabine Domvanalimab | 18 Years - | Gilead Sciences | |
| Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC | NCT06055738 | Locally Advance... | Zimberelimab Albumin-bound P... Cisplatin | 18 Years - | Tang-Du Hospital | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies | NCT05329766 | Gastrointestina... | Domvanalimab Quemliclustat Zimberelimab Fluorouracil Leucovorin Oxaliplatin | 18 Years - | Arcus Biosciences, Inc. | |
| Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors | NCT06082960 | Solid Tumors | GS-9911 Zimberelimab | 18 Years - | Gilead Sciences | |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05177770 | Metastatic Cast... Prostate Cancer | SRF617 etrumadenant zimberelimab | 18 Years - | Coherus Biosciences, Inc. | |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | NCT04772989 | Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc... | AB308 Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | NCT04772989 | Advanced Solid ... Non Small Cell ... Melanoma Cervical Cancer Multiple Myelom... Lymphoma, Non-H... Diffuse Large B... Gastric Cancer Gastroesophagea... Esophageal Canc... | AB308 Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer | NCT05676931 | Advanced Non-Sm... | Domvanalimab Quemliclustat Zimberelimab Docetaxel Platinum-Based ... | 18 Years - | Arcus Biosciences, Inc. | |
| Switch Maintenance in Pancreatic | NCT05419479 | Pancreatic Canc... Adenocarcinoma ... Squamous Cell C... Adenosquamous C... | ZIMBERELIMAB DOMVANALIMAB APX005M FOLFIRI | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | NCT05335941 | Urothelial Carc... Metastatic Canc... | Pemetrexed Zimberelimab Etrumadenant | 18 Years - | M.D. Anderson Cancer Center | |
| SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) | NCT06009029 | Locally Advance... | Stereotactic bo... Zimberelimab (G... | 18 Years - 75 Years | Peking University Third Hospital | |
| A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | NCT06120075 | Advanced Cancer | AB801 Zimberelimab Docetaxel | 18 Years - | Arcus Biosciences, Inc. | |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | NCT03629756 | Non-small Cell ... Squamous Cell C... Breast Cancer Colorectal Canc... Melanoma Bladder Cancer Ovarian Cancer Endometrial Can... Merkel Cell Car... GastroEsophagea... Renal Cell Carc... Castration-resi... | Etrumadenant Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer | NCT05502237 | Non-small Cell ... | Zimberelimab Domvanalimab Pembrolizumab Carboplatin Cisplatin Paclitaxel Nab-paclitaxel Pemetrexed | 18 Years - | Gilead Sciences | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | NCT05335941 | Urothelial Carc... Metastatic Canc... | Pemetrexed Zimberelimab Etrumadenant | 18 Years - | M.D. Anderson Cancer Center | |
| Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors | NCT05007782 | Advanced Solid ... | GS-1811 Zimberelimab | 18 Years - | Gilead Sciences |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
